168 related articles for article (PubMed ID: 38791816)
1. LAI-ART Awareness, Willingness, Barriers and Facilitators among Black Sexual Minority Men Living with HIV in the US South.
Campbell CK; Kielhold K; Reynolds HE; Vincent W; Siconolfi DE; Ramos SD; Ogunbajo A; Kegeles SM; Storholm ED
Int J Environ Res Public Health; 2024 May; 21(5):. PubMed ID: 38791816
[TBL] [Abstract][Full Text] [Related]
2. Willingness to Use Long-Acting Injectable PrEP Among PrEP Naïve Black and Hispanic Sexual Gender Minority Persons.
Okafor CN; Eaton L; Watson R
AIDS Behav; 2024 Jun; 28(6):2166-2174. PubMed ID: 38526639
[TBL] [Abstract][Full Text] [Related]
3. Examining the Awareness, Acceptability, and Adoption of Conventional and non-conventional Forms of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention Among jail-involved Black Sexual Minority men (BSMM) and Black Transgender Women (BTW) in Two Diverse US Cities.
Jones MD; Jones K; Almirol E; Payne G; Graves B; Schneider JA; Rijos D; Zawitz C; Zimmerman R; Seal DW; Brewer R; DrPH RB
AIDS Behav; 2023 Apr; 27(4):1304-1313. PubMed ID: 36264406
[TBL] [Abstract][Full Text] [Related]
4. Willingness to use and preferences for long-acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021-2022: cross-sectional study.
Schoenberg P; Edwards OW; Merrill L; Martinez CA; Stephenson R; Sullivan PS; Jones J
J Int AIDS Soc; 2023 Mar; 26(3):e26077. PubMed ID: 36951057
[TBL] [Abstract][Full Text] [Related]
5. Multisite Study of Women Living With HIV's Perceived Barriers to, and Interest in, Long-Acting Injectable Antiretroviral Therapy.
Philbin MM; Parish CL; Kinnard EN; Reed SE; Kerrigan D; Alcaide ML; Cohen MH; Sosanya O; Sheth AN; Adimora AA; Cocohoba J; Goparaju L; Golub ET; Fischl M; Metsch LR
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):263-270. PubMed ID: 32530905
[TBL] [Abstract][Full Text] [Related]
6. High Acceptability and Perceived Feasibility of Long-Acting Injectable Antiretroviral Treatment Among People Living with HIV Who Are Viremic and Health Workers in Uganda.
Kennedy CE; Zhao T; Vo AV; Nakubulwa R; Nabakka P; Jackson J; Rosen JG; Chang LW; Reynolds SJ; Quinn TC; Nakigozi G; Kigozi G; Kagaayi J; Nalugoda F; Ddaaki WG; Grabowski MK; Nakyanjo N
AIDS Patient Care STDS; 2023 Jun; 37(6):316-322. PubMed ID: 37294280
[TBL] [Abstract][Full Text] [Related]
7. Perspectives Among Health Care Providers and People with HIV on the Implementation of Long-Acting Injectable Cabotegravir/Rilpivirine for Antiretroviral Therapy in Florida.
Fisk-Hoffman RJ; Ranger SS; Gracy A; Gracy H; Manavalan P; Widmeyer M; Leeman RF; Cook RL; Canidate S
AIDS Patient Care STDS; 2024 Jun; 38(6):275-285. PubMed ID: 38686517
[TBL] [Abstract][Full Text] [Related]
8. Examining adherence barriers among women with HIV to tailor outreach for long-acting injectable antiretroviral therapy.
Benning L; Mantsios A; Kerrigan D; Coleman JS; Golub E; Blackstock O; Konkle-Parker D; Philbin M; Sheth A; Adimora AA; Cohen MH; Seidman D; Milam J; Kassaye SG; Taylor T; Murray M
BMC Womens Health; 2020 Jul; 20(1):152. PubMed ID: 32711509
[TBL] [Abstract][Full Text] [Related]
9. Perceptions of Long-Acting Injectable Antiretroviral Therapy Among People Living with HIV Who Use Drugs and Service Providers: a Qualitative Analysis in Rhode Island.
Collins AB; Macon EC; Langdon K; Joseph R; Thomas A; Dogon C; Beckwith CG
J Urban Health; 2023 Oct; 100(5):1062-1073. PubMed ID: 37563518
[TBL] [Abstract][Full Text] [Related]
10. Long-Acting Injectable Antiretrovirals for HIV Treatment: A Multi-Site Qualitative Study of Clinic-Level Barriers to Implementation in the United States.
McCrimmon T; Collins LF; Perez-Brumer A; Bazzi AR; Shaffer VA; Kerrigan D; Alcaide ML; Philbin MM
AIDS Patient Care STDS; 2024 Feb; 38(2):61-69. PubMed ID: 38381949
[TBL] [Abstract][Full Text] [Related]
11. Acceptability of Long-Acting Injectable Antiretroviral Therapy Among People with HIV Receiving Care at Three Ryan White Funded Clinics in the United States.
Erguera XA; Koester KA; Diaz Tsuzuki M; Dance KV; Flores R; Kerman J; McNulty MC; Colasanti JA; Collins LF; Montgomery ET; Johnson MO; Sauceda JA; Christopoulos KA
AIDS Behav; 2024 Jul; 28(7):2226-2238. PubMed ID: 38598026
[TBL] [Abstract][Full Text] [Related]
12. Acceptability of and Preferences for Long-Acting Injectable HIV PrEP and Other PrEP Modalities among Sexual Minority Men in Nigeria, Africa.
Ogunbajo A; Tsai AC; Kanki PJ; Mayer KH
AIDS Behav; 2022 Jul; 26(7):2363-2375. PubMed ID: 35061117
[TBL] [Abstract][Full Text] [Related]
13. Preference for using a variety of future HIV pre-exposure prophylaxis products among men who have sex with men in three US cities.
Mansergh G; Kota KK; Stephenson R; Hirshfield S; Sullivan P
J Int AIDS Soc; 2021 Jan; 24(1):e25664. PubMed ID: 33481359
[TBL] [Abstract][Full Text] [Related]
14. Pre-exposure prophylaxis for HIV prevention preferences among young adult African American men who have sex with men.
Patel RR; Crane JS; López J; Chan PA; Liu AY; Tooba R; James AS
PLoS One; 2018; 13(12):e0209484. PubMed ID: 30592756
[TBL] [Abstract][Full Text] [Related]
15. Perceived Barriers to and Facilitators of Long-Acting Injectable HIV PrEP Use Among Black, Hispanic/Latino, and White Gay, Bisexual, and Other Men Who Have Sex With Men.
Tran NK; Martinez O; Scheim AI; Goldstein ND; Welles SL
AIDS Educ Prev; 2022 Oct; 34(5):365-378. PubMed ID: 36181495
[TBL] [Abstract][Full Text] [Related]
16. Willingness to take long-acting injectable pre-exposure prophylaxis among men who have sex with men who participated in the CROPrEP study: a cross-sectional online study.
Liu Y; Chu Z; Wang H; Huang X; Chen Y; Wang H; Zou D; Jiang Y; Geng W; Hu Q; Zhou B; Shang H
BMC Public Health; 2023 Dec; 23(1):2494. PubMed ID: 38093204
[TBL] [Abstract][Full Text] [Related]
17. Barriers and Facilitators for Antiretroviral Treatment Adherence Among HIV-Positive African American and Latino Men Who Have Sex With Men.
Carey JW; Carnes N; Schoua-Glusberg A; Kenward K; Gelaude D; Denson DJ; Gall E; Randall LA; Frew PM
AIDS Educ Prev; 2019 Aug; 31(4):306-324. PubMed ID: 31361514
[TBL] [Abstract][Full Text] [Related]
18. A Qualitative Exploration of Women's Interest in Long-Acting Injectable Antiretroviral Therapy Across Six Cities in the Women's Interagency HIV Study: Intersections with Current and Past Injectable Medication and Substance Use.
Philbin MM; Parish C; Bergen S; Kerrigan D; Kinnard EN; Reed SE; Cohen MH; Sosanya O; Sheth AN; Adimora AA; Cocohoba J; Goparaju L; Golub ET; Fischl M; Alcaide ML; Metsch LR
AIDS Patient Care STDS; 2021 Jan; 35(1):23-30. PubMed ID: 33400587
[TBL] [Abstract][Full Text] [Related]
19. Barriers and Facilitators of PrEP Adherence for Young Men and Transgender Women of Color.
Wood S; Gross R; Shea JA; Bauermeister JA; Franklin J; Petsis D; Swyryn M; Lalley-Chareczko L; Koenig HC; Dowshen N
AIDS Behav; 2019 Oct; 23(10):2719-2729. PubMed ID: 30993479
[TBL] [Abstract][Full Text] [Related]
20. Conducting Virtual, Synchronous Focus Groups Among Black Sexual Minority Men: Qualitative Study.
Dangerfield Ii DT; Wylie C; Anderson JN
JMIR Public Health Surveill; 2021 Feb; 7(2):e22980. PubMed ID: 33427671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
